Key facts
- Notable investors include Imperial Enterprise Lab, Zinc, Accelerate Cambridge.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Genosys Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Genosys Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genosys Bio
Developer of gene-expression optimization technology intended to improve biologic drug manufacturing efficiency and reduce production costs. The company's platform uses AI models trained on regulatory DNA-sequence datasets and systematic gene-architecture design, enabling Contract Development Manufacturing Organizations and biotech innovators to deploy optimized expression constructs for biologic production and scale manufacturing workflows more cost-effectively.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 2
- Website
- genosysbio.com/
- Ownership
- Privately Held (backing)
Genosys Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genosys Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genosys Bio in its N-PORT filings yet. We sweep new filings monthly.